adjuvanted flu-v
Vaccineexperimental
Clinical trial activity
2 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02962908)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adjuvanted flu-v
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03180801 | Phase 2 | Aug 18, 2016 | Hammersmith Medicines Research, hVIVO Services Limited, National Institute of Allergy and Infectious Diseases (NIAID), SEEK |
| NCT02962908 | Phase 2 | Aug 1, 2016 | Government of Norway, Isala Clinics, Zwolle, The Netherlands, Robert Koch Institut, SEEK, University of Groningen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SEEK | For profit | 2 | 2 | 1 | 2016 |
| Government of Norway | Government | 1 | 0 | 1 | 2016 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2016 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2016 |
| Isala Clinics, Zwolle, The Netherlands | Academic/Hospital | 1 | 0 | 1 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2016 |
| Robert Koch Institut | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2016 |
8 organizations
Page 1 / 1